(+)-Naloxone

(+)-Naloxone
Clinical data
MedlinePlus a601092
Legal status
Legal status
  • Uncontrolled
Identifiers
PubChem (CID) 5491858
ChemSpider 4590735 YesY
Chemical and physical data
Formula C19H21NO4
Molar mass 327.374 g/mol
3D model (Jmol) Interactive image
  (verify)

(+)-Naloxone (dextro-naloxone) is a drug which is the "unnatural" enantiomer of the opioid antagonist drug (−)-naloxone. Unlike "normal" naloxone, (+)-naloxone has no significant affinity for opioid receptors,[1] but instead has been discovered to act as a selective antagonist of Toll-like receptor 4. This receptor is involved in immune system responses, and activation of TLR4 induces glial activation and release of inflammatory mediators such as TNF-α and Interleukin-1.[2][3]

Relation of TLR4 to opioid drugs

Both "normal" and "unnatural" enantiomers of various opioid analgesic drugs including morphine, meperidine, fentanyl, methadone and buprenorphine, as well as some otherwise inactive metabolites like morphine-3-glucuronide, have been found to act as agonists of TLR4, and chronic use of these drugs consequently causes constant low-level release of TNF-α and IL-1β as well as other downstream effects. This is thought to be involved in various adverse properties of opioid analgesic drugs, such as loss of efficacy with extended use and the associated development of tolerance and dependence, as well as the development of side effects such as hyperalgesia and allodynia, which can cause long-term use of opioid analgesics to not only fail to treat neuropathic pain, but ultimately exacerbate it.[4][5]

Applications of (+)-naloxone and related drugs

Several opioid antagonist drugs were found to act as antagonists for TLR4, including naloxone and naltrexone. However it was found that not only the "normal" (-) enantiomers, but also the "unnatural" (+) enantiomers of these drugs acted as TLR4 antagonists (though (+)-nalmefene was inactive). Since (+)-naloxone and (+)-naltrexone lack affinity for opioid receptors, they do not block the effects of opioid analgesic drugs, and so can be used to counteract the TLR4-mediated side effects of opioid agonists without affecting analgesia,[6] though (+)-naloxone does reduce the reinforcing effects of opioid drugs.[7] (+)-Naloxone was also found to be neuroprotective,[8][9] and both (+)-naloxone and (+)-naltrexone are effective in their own right at treating symptoms of neuropathic pain in animal models.[10][11] However (+)-naloxone was also found to reduce the effects of stimulant drugs,[12][13] suggesting additional actions beyond TLR4 antagonism (possibly as a sigma receptor antagonist),[14] that might potentially result in unwanted side effects or drug interactions.

See also

References

  1. ↑ Iijima, I.; Minamikawa, J.; Jacobson, A. E.; Brossi, A.; Rice, K. C.; Klee, W. A. (1978). "Studies in the (+)-morphinan series. 5. Synthesis and biological properties of (+)-naloxone". Journal of Medicinal Chemistry. 21 (4): 398–400. doi:10.1021/jm00202a018. PMID 206698.
  2. ↑ Wu, Hsiang-En; Thompson, Jonathan; Sun, Han-Sen; Terashvili, Maia; Tseng, Leon F. (September 2005). "Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord". The Journal of Pharmacology and Experimental Therapeutics. 314 (3): 1101–8. doi:10.1124/jpet.105.087130. PMID 15901793.
  3. ↑ Watkins, Linda R.; Hutchinson, Mark R.; Rice, Kenner C.; Maier, Steven F. (2009). "The "Toll" of Opioid-Induced Glial Activation: Improving the Clinical Efficacy of Opioids by Targeting Glia". Trends in Pharmacological Sciences. 30 (11): 581–591. doi:10.1016/j.tips.2009.08.002. PMC 2783351Freely accessible. PMID 19762094.
  4. ↑ Hutchinson, Mark R.; Zhang, Yingning; Shridhar, Mitesh; Evans, John H.; Buchanan, Madison M.; Zhao, Tina X.; Slivka, Peter F.; Coats, Benjamen D.; Rezvani, Niloofar; Wieseler, Julie; Hughes, Travis S.; Landgraf, Kyle E.; Chan, Stefanie; Fong, Stephanie; Phipps, Simon; Falke, Joseph J.; Leinwand, Leslie A.; Maier, Steven F.; Yin, Hang; Rice, Kenner C.; Watkins, Linda R. (2010). "Evidence that opioids may have toll-like receptor 4 and MD-2 effects". Brain, Behavior, and Immunity. 24 (1): 83–95. doi:10.1016/j.bbi.2009.08.004. PMC 2788078Freely accessible. PMID 19679181.
  5. ↑ Hutchinson, Mark R.; Lewis, S. S.; Coats, Benjamen D.; Rezvani, Niloofar; Zhang, Y.; Wieseler, Julie L.; Somogyi, A. A.; Yin, Hang; Maier, Steven F.; Rice, Kenner C.; Watkins, Linda R. (19 May 2010). "Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences". Neuroscience. 167 (3): 880–893. doi:10.1016/j.neuroscience.2010.02.011. PMC 2854318Freely accessible. PMID 20178837.
  6. ↑ Wu, Hsiang-En; Sun, Han-Sen; Cheng, Caleb W.; Terashvili, Maia; Tseng, Leon F. (November 2006). "dextro-Naloxone or levo-naloxone reverses the attenuation of morphine antinociception induced by lipopolysaccharide in the mouse spinal cord via a non-opioid mechanism". The European Journal of Neuroscience. 24 (9): 2575–2580. doi:10.1111/j.1460-9568.2006.05144.x. PMID 17100845.
  7. ↑ Hutchinson, M. R.; Northcutt, A. L.; Hiranita, T.; Wang, X.; Lewis, S. S.; Thomas, J.; Van Steeg, K.; Kopajtic, T. A.; Loram, L. C.; Sfregola, C.; Galer, E.; Miles, N. E.; Bland, S. T.; Amat, J.; Rozeske, R. R.; Maslanik, T.; Chapman, T. R.; Strand, K. A.; Fleshner, M.; Bachtell, R. K.; Somogyi, A. A.; Yin, H.; Katz, J. L.; Rice, K. C.; Maier, S. F.; Watkins, L. R. (15 August 2012). "Opioid Activation of Toll-Like Receptor 4 Contributes to Drug Reinforcement". Journal of Neuroscience. 32 (33): 11187–11200. doi:10.1523/JNEUROSCI.0684-12.2012. PMC 3454463Freely accessible. PMID 22895704.
  8. ↑ Liu, Bin; Du, Lina; Hong, Jau-Shyong (1 May 2000). "Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation". The Journal of Pharmacology and Experimental Therapeutics. 293 (2): 607–617. PMID 10773035.
  9. ↑ Liu, Yuxin; Qin, Liya; Wilson, Belinda C.; An, Lijia; Hong, Jau-Shyong; Liu, Bin (1 September 2002). "Inhibition by naloxone stereoisomers of β-amyloid peptide (1-42)-induced superoxide production in microglia and degeneration of cortical and mesencephalic neurons". The Journal of Pharmacology and Experimental Therapeutics. 302 (3): 1212–1219. doi:10.1124/jpet.102.035956. PMID 12183682.
  10. ↑ Hutchinson, Mark R.; Zhang, Yingning; Brown, Kimberley; Coats, Benjamen D.; Shridhar, Mitesh; Sholar, Paige W.; Patel, Sonica J.; Crysdale, Nicole Y.; Harrison, Jacqueline A.; Maier, Steven F.; Rice, Kenner C.; Watkins, Linda R. (July 2008). "Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4)". European Journal of Neuroscience. 28 (1): 20–29. doi:10.1111/j.1460-9568.2008.06321.x. PMC 2588470Freely accessible. PMID 18662331.
  11. ↑ Lewis, Susannah S.; Loram, Lisa C.; Hutchinson, Mark R.; Li, Chien-Ming; Zhang, Yingning; Maier, Steven F.; Huang, Yong; Rice, Kenner C.; Watkins, Linda R. (2012). "(+)-Naloxone, an Opioid-Inactive Toll-Like Receptor 4 Signaling Inhibitor, Reverses Multiple Models of Chronic Neuropathic Pain in Rats". The Journal of Pain. 13 (5): 498–506. doi:10.1016/j.jpain.2012.02.005. PMC 3348259Freely accessible. PMID 22520687.
  12. ↑ Chatterjie, Nithiananda; Alexander, George J.; Sechzer, Jeri A.; Lieberman, Kenneth W. (June 1996). "Prevention of cocaine-induced hyperactivity by a naloxone isomer with no opiate antagonist activity". Neurochemical Research. 21 (6): 691–3. doi:10.1007/BF02527726. PMID 8829141.
  13. ↑ Chatterjie, Nithiananda; Sechzer, Jeri A.; Lieberman, Kenneth W.; Alexander, George J. (February 1998). "Dextro-naloxone counteracts amphetamine-induced hyperactivity". Pharmacology, Biochemistry and Behavior. 59 (2): 271–274. doi:10.1016/S0091-3057(97)00528-5. PMID 9476969.
  14. ↑ Wu, Hsiang-en; Hong, Jau-Shyong; Tseng, Leon F. (1 October 2007). "Stereoselective action of (+)-morphine over (−)-morphine in attenuating the (−)-morphine-produced antinociception via the naloxone-sensitive sigma receptor in the mouse". European Journal of Pharmacology. 571 (2–3): 145–151. doi:10.1016/j.ejphar.2007.06.012. PMC 2080825Freely accessible. PMID 17617400.
This article is issued from Wikipedia - version of the 9/26/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.